-
Can’t Get You Out of My Head: The Huntington’s Disease Symptom That’s More Than Just Repetition
5 min read
Latest News
-
AMT-130 at Four Years: Hopeful Signs, Complex Controls
12 min read
uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.
-
Huntington’s Disease Clinical Research Congress 2025 – Day 3
30 min read
Catch up on all the latest HD news from Day 3 of the Huntington’s Disease Clinical Research Congress in Nashville, USA.
-
Huntington’s Disease Clinical Research Congress 2025 – Day 2
23 min read
Catch up on all the latest HD news from Day 2 of the Huntington’s Disease Clinical Research Congress in Nashville, USA.
-
Huntington’s Disease Clinical Research Congress 2025 – Day 1
11 min read
Catch up on all the latest HD news from Day 1 of the Huntington’s Disease Clinical Research Congress in Nashville, USA.
-
Controlling DNA Scanning Machines to Slow Expansion of CAG Repeats
5 min read
A new study identifies small molecules that target a DNA repair machine, opening a potential path to delay Huntington’s disease onset.
-
2025 HDBuzz Prize: When Good Huntingtin Goes Missing: A Step Toward Designing Safe HD Treatments
7 min read
We’re proud to announce Gravity Guignard as a 2025 HDBuzz Prize winner! A new study points to one of the reasons why past HD trials might have failed. The good news? This shows the path to safer drugs, getting us closer to effective therapies.
-
2025 HDBuzz Prize: On the Frontlines: Trusting the Hall Monitors of the Cell
5 min read
We’re proud to announce Chloe Langridge as a 2025 HDBuzz Prize winner! A protein called SGTA shows promise as a target in HD therapeutics. Researchers find that increasing levels of SGTA in the cell helps reduce signs of HD.
-
September 2025: This Month in Huntington’s Disease Research
5 min read
September was a landmark month in Huntington’s disease research: a gene therapy shows signs of slowing progression, plus new biomarkers, mechanistic insights and mental health advances. The field has come far and exciting directions lie ahead.
-
The First Domino Falls: AMT-130 Gene Therapy Slows Huntington’s in Landmark Trial
15 min read
In an update from uniQure, they report that their experimental gene therapy, AMT-130, has the potential to slow Huntington’s disease progression in key clinical study.
-
2025 HDBuzz Prize: When the Repair Crew Breaks Down: How Expanded Huntingtin Disrupts DNA Repair
8 min read
We’re proud to announce Mustafa Mehkary as a 2025 HDBuzz Prize winner! New findings reveal that the huntingtin protein is a key player in the cell’s DNA repair crew. In HD, the crew falls apart leaving DNA damage and alarm bells ringing in its wake.
-
SKY-0515 Lowers Huntingtin In People With Huntington’s Disease In Trial Update
8 min read
SKY-0515, an oral drug, safely lowers huntingtin in people with HD and may also reduce PMS1. This could offer a possible two-pronged approach to treat HD. SKY-0515 is now being tested in a larger Phase 2/3 trial.
HDBuzz Trial Tracker
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
